Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance

Clinical trial NCT05178511 · UNKNOWN

Trial details

NCT number: NCT05178511
Sponsor: Li Zhang, MD
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

The Diagnosis Was ALK Positive NSCLC Second Generation ALK-TKI is Resistant Efficacy of Ensatinib in This Subset of Patients

Start date: 2021-12-01
Primary completion: 2023-07-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.